Active Stocks
Thu Feb 29 2024 15:49:54
  1. Kotak Mahindra Bank share price
  2. 1,690.80 0.43%
  1. Axis Bank share price
  2. 1,075.70 0.10%
  1. Tata Steel share price
  2. 140.90 0.11%
  1. Power Grid Corporation Of India share price
  2. 282.55 1.07%
  1. ITC share price
  2. 406.50 -0.51%
Business News/ Science / Health/  Covishield side-effects: India to review COVID-19 vaccine after concerns in Europe
BackBack

Covishield side-effects: India to review COVID-19 vaccine after concerns in Europe

The news came after several countries had suspended rollout of AstraZeneca coronavirus vaccine over blood clot fears
  • However, no cases of blood clots have been reported so far in the country, according to reports
  • India earlier granted emergency use approval to Covishield by Serum Institute of India and Covaxin by Bharat Biotech (REUTERS)Premium
    India earlier granted emergency use approval to Covishield by Serum Institute of India and Covaxin by Bharat Biotech (REUTERS)

    The central government decided to conduct a deeper review of post-vaccination side-effects from the Oxford-AstraZeneca coronavirus vaccine, news agency AFP reported on Saturday. The news came after several countries had suspended rollout of AstraZeneca shot over blood clot fears. However, no cases of blood clots have been reported so far in the country, AFP said.

    Denmark, Norway and Iceland paused use of Oxford-AstraZeneca coronavirus vaccine as a precaution after isolated reports of recipients developing blood clots.

    The local version of Oxford-AstraZeneca COVID-19 vaccine is known as Covishield. Serum Institute of India, the world's largest vaccine manufacturer by volume, joined hands with AstraZeneca to produce 1 billion doses of its COVID-19 vaccine.

    "We are looking at all the adverse events, particularly serious adverse events like deaths and hospitalisation. We will come back if we find anything of concern," N.K. Arora, a member of India's national task force on COVID-19 told news agency AFP.

    Arora said there was "no immediate issue of concern as number of adverse events (in India) is very, very low. We are relooking at (adverse events that were reported) to see if there was any issue of blood clotting."

    "As of yesterday there were 59 or 60 deaths, and they were all coincidental," the doctor said, according to AFP.

    "In fact there is a real effort from our side that once complete investigation is done, to put its results in public domain, on the ministry of health website," Arora added, AFP reported.

    India earlier granted emergency use approval to Covishield by Serum Institute of India and Covaxin by Bharat Biotech.A total of 16,39,663 beneficiaries that included health care workers (HCW) and front line workers (FLW) were vaccinated the first dose and 4,13,874 people received the second dose of the vaccine. So far, a cumulative total of 2,82,18,457 doses of the vaccine have been administered.

    "Some states in the country have been reporting very high number of daily new Covid cases. Maharashtra, Kerala, Punjab, Karnataka, Gujarat and Tamil Nadu continue to report a surge in Covid daily cases," the health ministry said in a statement on Friday.

    India had registered 23,285 new cases in the last 24 hours, with the six states accounting for 85.6% of the new infections, it added.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 13 Mar 2021, 02:53 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App